A Bivalent Conjugate Vaccine for Malaria and Typhoid Prophylaxis

Malaria is the single leading cause of mortality, especially among children in the developing world. Typhoid fever, caused by infection withSalmonella typhi, is known to be endemic with malaria and causes its own significant disease burden. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have developed a novel bivalent vaccine candidate that may effectively prevent malaria and typhoid. This approach significantly enhances immune response to the Pfs25 Malaria transmission blocking antigen and produces a robust immune response againstSalmonella typhi Vi polysaccharide (ViP).IC: International Vaccine InstituteNIH Ref. No.: E-124-2016/0Advantages: This technology has significant advantages over current treatments, since there is currently only one commercial Malaria vaccine licensed for use in Europe only, which was not developed to address Malaria transmission, and the currently licensed Salmonella typhi vaccines show incomplete efficacy and do not provide long-term immunity. A formulation of the present technology has shown the ability to induce an immune response to Pfs25 in excess of 100 times higher and Salmonella typhi antigen 20-40 times higher than what is seen by immunization with either antigen alone.Applications: Development of this technology into a vaccine may protect vulnerable populations from both Malaria transmission and Typhoid fever.Provider Technology ID: 3107U...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research